About
portfolio
team
news
Contact
EN
CN
Give your business a boost with a beautifully crafted homepage.
News
Click below to follow us on LinkedIn and view our latest shares
Follow us ON LINKEDIN
Or Subscribe to Our Quarterly Newsletter Below
August 30, 2023
I
Shanghai
Latest Updates of Viva's Portfolio Companies
August 25, 2023
I
Shanghai
ABM Therapeutics receives IND approval in China for MEK inhibitor ABM-168
August 21, 2023
I
Shanghai
Arthrosi Therapeutics AR882 Prepares to Enter into Global Phase 3 Study
August 11, 2023
I
Shanghai
AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease
August 2, 2023
I
Shanghai
U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with Glioblastoma Harboring BRAF V600 Mutation
July 30, 2023
I
Shanghai
Latest Updates of Viva's Portfolio Companies
July 20, 2023
I
Shanghai
Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
July 18, 2023
I
Shanghai
DTx Pharma Reached the Acquisition Agreement with Novartis
July 12, 2023
I
Shanghai
Arthrosi Secures $75M in Series D Financing
July 7, 2023
I
Shanghai
Latest Updates of 5 Viva's Portfolio Companies
June 9, 2023
I
Shanghai
DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)
June 5, 2023
I
Shanghai
Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities
June 5, 2023
I
Shanghai
VVN539, a dual-target innovative drug for glaucoma independently developed by VivaVision, reached the primary research endpoint in the Phase II clinical trial in the United States
June 2, 2023
I
Shanghai
Latest Updates of 7 Viva's Portfolio Companies
May 6, 2023
I
Shanghai
VivaVision Announced the Completion of Over 100 million RMB in Series D2 Financing
May 5, 2023
I
Shanghai
ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor
April 25, 2023
I
Shanghai
Latest Updates of 3 Viva's Portfolio Companies
April 19, 2023
I
Shanghai
Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial
April 4, 2023
I
Shanghai
Latest Updates of 6 Viva's Portfolio Companies
March 30, 2023
I
Shanghai
Viva Biotech Announced 2022 Annual Results
March 30, 2023
I
Shanghai
Everything You Need to Know about Viva Biotech 2022 Annual Results
March 16, 2023
I
Shanghai
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
March 14, 2023
I
Shanghai
AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform
March 13, 2023
I
Shanghai
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
March 2, 2023
I
Shanghai
AceLink Presented Phase I Clinical Data of AL01211 and AL00804 During the 2023 WORLD Symposium
February 10, 2023
I
Shanghai
Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial
February 10, 2023
I
Shanghai
Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023
February 9, 2023
I
Shanghai
AmacaThera's Lung Cancer Applications Recognized in QuickFire Challenge
February 6, 2023
I
Shanghai
Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023
January 31, 2023
I
Shanghai
TechnoDerma Completed the Series A+ Funding of Tens of Millions of RMB
January 13, 2023
I
Shanghai
QureBio Q-1801 Project was approved by CDE
January 9, 2023
I
Shanghai
VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases
January 9, 2023
I
Shanghai
ARTHROSI ANNOUNCES POSITIVE TOPLINE RESULTS FOR AR882 PHASE 2B STUDY
January 9, 2023
I
Shanghai
Exclusive Interview with Focus-X Therapeutics: Achieving Successful Acquisition within Two Years of Establishment, What Makes This Radiopharmaceutical Start-Up Stand Out?
January 6, 2023
I
Shanghai
Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors
December 26, 2022
I
Shanghai
2023 JPMorgan Week丨Reaching Beyond the Low-Hanging Fruits in Drug Discovery
November 30, 2022
I
Shanghai
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
November 15, 2022
I
Shanghai
Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001
November 3, 2022
I
Shanghai
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
October 26, 2022
I
Shanghai
Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors
October 20, 2022
I
Shanghai
Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease
October 13, 2022
I
Shanghai
ABM Therapeutics receives IND approval by FDA for MEK inhibitor ABM-168
September 16, 2022
I
Shanghai
ABM Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ABM-1310 in China
September 14, 2022
I
Shanghai
HAYA Therapeutics won the "TOP 100 Swiss Startup Award 2022" and was successfully selected for "Soonicorn Club 2022"
September 14, 2022
I
Shanghai
AceLink Therapeutics Receives Orphan Drug Designation for its Novel GCS inhibitor AL01211 for the Treatment of Fabry Disease
August 30, 2022
I
Shanghai
Regenacy Pharmaceuticals Announces Completion of Enrollment for Phase 2 Study in Diabetic Peripheral Neuropathy & $9.3 Million Series B Financing
August 10, 2022
I
Shanghai
Arthrosi Completes AR882 Renal Impairment Study
July 28, 2022
I
Shanghai
AIxplorerBIO and the Institute of Immunology at Tsinghua University Reached a Strategic Collaboration Agreement to Explore and Promote the R&D of New Drugs in the Field of Autoimmunity
June 30, 2022
I
Shanghai
Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology
June 28, 2022
I
Shanghai
Amberstone Biosciences Announces Formation of Scientific Advisory Board
June 27, 2022
I
Shanghai
Anji Pharma Provides Updates on Two Lead Programs
June 24, 2022
I
Shanghai
Viva Biotech Successfully Held The 3rd Annual Partnership Summit
May 31, 2022
I
Shanghai
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings
May 30, 2022
I
Shanghai
VivaVision and Acemab Reached a Strategic Collaboration Agreement, To Jointly Develop Antibody Drugs For Fundus Diseases
May 18, 2022
I
Shanghai
AIxplorerBio and PaddleHelix Reached A Deep Collaboration to Promote the Construction of AI Small Molecule Drug R＆D System
May 16, 2022
I
Shanghai
【R.S.V.P.】Viva Biotech 2022 Partnership Summit
May 11, 2022
I
Shanghai
Domain Therapeutics raises $42m Series A financing
May 5, 2022
I
Shanghai
VivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application
April 27, 2022
I
Shanghai
Dr. Kasper Roet, CEO of QurAlis, selected for the 2022 Henri Termeer Award
April 12, 2022
I
Shanghai
QureBio's First Bispecific Antibody Q-1802 Combination Clinical Trial (Phase I/II) Was Approved
March 31, 2022
I
Shanghai
Triumvira Immunologics Completes Extension of Series A Financing, for Total Round of Approximately $100 Million
March 30, 2022
I
Shanghai
Apeiron Closes $17.5 Million Series A and Launches New Strategic Partnerships with Viva Biotech
March 28, 2022
I
Shanghai
Viva Biotech Announces 2021 Annual Results
March 23, 2022
I
Shanghai
VivaVision Biotech Announces Positive Top Line Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease
March 18, 2022
I
Shanghai
Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests
March 4, 2022
I
Shanghai
ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance
February 22, 2022
I
Shanghai
On a quest to solve the biggest problem in stroke therapy
December 14, 2021
I
Shanghai
Arthrosi Therapeutics, Inc. Announces Patient Enrollment in Global Phase 2b Study of AR882
December 8, 2021
I
Shanghai
Join VBI and J&J on Dec 8 with the "The Dos & Don’ts of Fundraising"
November 16, 2021
I
Shanghai
Deka Biosciences Raises USD 20 Million in Series A Financing
November 15, 2021
I
Shanghai
Fuse Biotherapeutics Raises an Oversubscribed and Upsized Seed Financing Round of $9.5 Million
October 29, 2021
I
Shanghai
2021 VBI Demo Day Review丨IND and Beyond: Presenting Highlights from 6 VBI Portfolio Companies
October 27, 2021
I
Shanghai
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting
October 19, 2021
I
Shanghai
VBI DemoDay on Oct 29th
October 6, 2021
I
Shanghai
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry
October 6, 2021
I
Shanghai
Viva BioInnovator Venture Day with NewYorkBio & Biocom California
September 28, 2021
I
Shanghai
Looking to rewrite the rules of drug licensing, startup Anji is on the hunt for 'dynamic equity' joint ventures
September 27, 2021
I
Shanghai
AmacaThera named CIX Top 20 Early company
September 22, 2021
I
Shanghai
Triumvira is Creating a Different Picture for Cancer Patients
September 17, 2021
I
Shanghai
Hengrui Medicine's Apatinib and Qiyu Bio-Q-1802 announced a strategic cooperation for a Phase II clinical study of advanced gastric cancer
September 15, 2021
I
Shanghai
Simon Sturge Joins Mediar Therapeutics as Executive Chairman
August 31, 2021
I
Shanghai
ABM Therapeutics and Sansheng Pharmaceuticals Announced a Strategic Cooperation to Accelerate the Development of Innovative Drugs
August 31, 2021
I
Shanghai
Viva Biotech Announced 2021 Interim Results
August 4, 2021
I
Shanghai
Viva BioInnovator was Included in the First Batch of GOIs
July 27, 2021
I
Shanghai
Absci was Successfully Listed on NASDAQ
July 1, 2021
I
Shanghai
Anj900 was Approved to Launch Key Phase III Clinical Trials in China
June 24, 2021
I
Shanghai
Langhua works with VivaVision to Successfully Develop Clinical Samples and CMC Scale Up
June 21, 2021
I
Shanghai
QureBio Announces the Enrollment of First Patient in Phase I Clinical Trial
June 18, 2021
I
Shanghai
Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials
June 16, 2021
I
Shanghai
Totient, a Viva Biotech Portfolio Company, is Acquired by AbSci
June 11, 2021
I
Shanghai
Anji Pharma Launches Phase 3 Trial for ANJ900
June 9, 2021
I
Shanghai
Haya Included in the Top 15 Swiss Biotech Startups Making a Difference in Europe
May 11, 2021
I
Shanghai
Shanghai EPN and BioMap Reached a Strategic Cooperation
May 11, 2021
I
Shanghai
TechnoDerma Announced New Progress in Phase I Clinical Trials of TDM-105795 in the U.S.
May 10, 2021
I
Shanghai
Viva Biotech and BioMap Reached a Strategic Collaboration Agreement
April 21, 2021
I
Shanghai
Anji Pharmaceutical Accelerates Phase II Clinical Study of ANJ908
April 19, 2021
I
Shanghai
VivaVision Completed 300 Million RMB Series D Financing
April 15, 2021
I
Shanghai
Viva Biotech Awarded 2021 Greater China CRO Entrepreneurial Company of the Year
April 14, 2021
I
Shanghai
TechnoDerma Medicines announced the completion of Series A Financing
March 30, 2021
I
Shanghai
Viva Biotech Announced 2020 Annual Results The Group’s Revenue Surged by 115.7% YoY Revenue from the CFS Business Increased Significantly by 146.3% YoY
.png)
.png)
.png)
